The PLK1 inhibitor GSK461364A Is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations
Dive into the research topics of 'The PLK1 inhibitor GSK461364A Is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations'. Together they form a unique fingerprint.